Life sciences company Aptamer Group has secured two new contracts with one of the world’s top five pharmaceutical companies, it announced on Thursday, with an estimated worth of up to £0.22m.
In the evolving world of precision medicine, the need for methods that can measure biomolecules with supreme accuracy and specificity is paramount. Recognizing this, Associate Professor Yan Xu of the Graduate School of Engineering at Osaka Metropolitan University and his international research team have made a great stride in this direction. They have developed an innovative nanofluidic device capable of capturing single proteins stochastically and detecting them digitally at their naturally high concentrations. This breakthrough could potentially lay the foundation for the future of personalized disease prevention and treatment.